BIOHealthcare · Medical DevicesBIO Stock Forecast: Bio-Rad Laboratories, Inc. Price Predictions for 2026-2027
The 5 Wall Street analysts covering Bio-Rad Laboratories, Inc. hold a median 12-month price target of $300 — -10.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 82 of 100 as at 1 Aug 2026 — inside the top quartile. The factors read stronger than the Street's target implies. That gap is the story on this page.
BIO stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Bio-Rad Laboratories, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (95): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Revisions (40): Analysts have, on balance, been cutting their forecasts.
Size (17): Larger than most of the companies we track — more scrutinised, less often mispriced.
The rank is the raw material. Whether the rules would actually own Bio-Rad Laboratories, Inc. — and when they’d sell — is the membership.
BIO stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on BIO, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits −10.4% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 15 May 2026 | RBC Capital | Reinstates | Outperform | $320 |
| 1 May 2026 | Wells Fargo | Maintains | Equal-Weight | — |
| 7 Apr 2026 | Citigroup | Downgrade | Neutral | — |
| 16 Feb 2026 | Wells Fargo | Maintains | Equal-Weight | — |
| 30 Oct 2025 | Citigroup | Maintains | Buy | — |
| 30 Oct 2025 | Wells Fargo | Maintains | Equal-Weight | — |
| 1 Aug 2025 | RBC Capital | Maintains | Outperform | — |
| 1 Aug 2025 | Wells Fargo | Maintains | Equal-Weight | — |
| 9 June 2025 | Wells Fargo | Maintains | Equal-Weight | — |
| 2 May 2025 | Citigroup | Maintains | Buy | — |
| 2 May 2025 | RBC Capital | Maintains | Outperform | — |
| 2 May 2025 | UBS | Maintains | Buy | — |
| 17 Apr 2025 | Wells Fargo | Maintains | Equal-Weight | — |
| 12 Feb 2025 | Wells Fargo | Maintains | Equal-Weight | — |
| 14 Jan 2025 | RBC Capital | Reiterates | Outperform | — |
| 9 Dec 2024 | RBC Capital | Maintains | Outperform | — |
| 31 Oct 2024 | Citigroup | Maintains | Buy | — |
| 31 Oct 2024 | RBC Capital | Maintains | Outperform | — |
| 1 Oct 2024 | Citigroup | Upgrade | Buy | — |
| 27 Aug 2024 | Wells Fargo | Initiates | Equal-Weight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
BIO analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Bio-Rad Laboratories, Inc. (BIO) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 54.1×
- Price / sales
- 3.4×
- Price / book
- 1.3×
- EV / EBITDA
- 19.2×
Cheaper than 14% of US stocks
Cheaper than 38% of US stocks
Cheaper than 64% of US stocks
Cheaper than 17% of US stocks
- Revenue growth (YoY)
- 1.1%
- Earnings growth (YoY)
- 1.1%
- Gross margin
- 52.3%
- Operating margin
- 5.8%
- Net margin
- 6.5%
Higher than 32% of US stocks
Higher than 38% of US stocks
Higher than 67% of US stocks
Higher than 59% of US stocks
Higher than 64% of US stocks
- Return on equity
- 2.5%
- Return on assets
- 1.8%
- Dividend yield
- —
Higher than 48% of US stocks
Higher than 57% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
BIO vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. BIO appears on the weeks it earns a place.
Frequently asked questions about BIO stock
What is the BIO stock price forecast for 2026-2027?
The 5 Wall Street analysts covering Bio-Rad Laboratories, Inc. have a median 12-month price target of $300, with estimates ranging from $275 to $320. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is BIO stock a buy right now?
Of the 5 analysts covering Bio-Rad Laboratories, Inc., 1 rate it a Buy, 3 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Bio-Rad Laboratories, Inc. 82 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank BIO?
As at 1 Aug 2026, Bio-Rad Laboratories, Inc. ranks 82 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (95 of 100).
Will BIO stock go up?
No one can know that. What the data says: the median 12-month target from 5 analysts implies -10.4% from the last close, and Ticker Nerd's factor model ranks Bio-Rad Laboratories, Inc. 82 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the BIO stock forecast for 2030?
No analyst covering Bio-Rad Laboratories, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BIO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $275 to $320 over the next 12 months.
How has BIO stock performed over the past year?
Bio-Rad Laboratories, Inc. returned +17.6% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Bio-Rad Laboratories, Inc. do?
Bio-Rad Laboratories, Inc. develops, manufactures, and markets specialized products for the clinical diagnostics and life sciences markets.
About Bio-Rad Laboratories, Inc.
Bio-Rad Laboratories, Inc. develops, manufactures, and markets specialized products for the clinical diagnostics and life sciences markets. In clinical diagnostics, the company provides test systems and quality control solutions for clinical laboratories. In life sciences, it produces instruments and reagents for research, biopharmaceutical production, and food testing, with a leadership position in digital PCR technology. The company operates globally across the Americas, Europe, and Asia, serving pharmaceutical companies, research institutions, clinical laboratories, and bioprocessing manufacturers. Bio-Rad also maintains a significant ownership stake in Sartorius, a supplier specializing in single-use bioprocessing technology. Founded in 1952 and headquartered in Hercules, California, the company operates a razor-and-blade business model in clinical diagnostics, combining durable instruments with recurring sales of consumable products and reagents to maintain steady revenue streams.
CEO Mr. Norman D. Schwartz · 7,450 employees · United States · https://www.bio-rad.com